Daprodustat vs Recombinant Human Erythropoietin for Anemia and Cardiovascular Safety in Dialysis-Dependent and Non-Dialysis-Dependent CKD Patients - A Systematic Review and Meta-analysis
Daprodustat offers a promising alternative to traditional anemia treatments in CKD, with efficacy comparable to rhEPO and a favorable cardiovascular safety profile, which marks its potential as a valuable therapeutic option.
Authors
- Shubhima Grover
- Hara Prasad Mishra (ORCID: https://orcid.org/0000-0001-9405-7822)
- Rachna Gupta
- LK Gupta
Institutions
- University of Delhi (IN)
- Lady Hardinge Medical College (IN)
- University College of Medical Sciences (IN)
Publication Details
- Journal
- Current Reviews in Clinical and Experimental Pharmacology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.2174/0127724328377421251117050736
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00